At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 630 enrolled
Drug / intervention
Ivermectin Cream, 1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea
In Brief
A Phase 3 clinical trial evaluating Ivermectin Cream, 1% and Placebo/Vehicle cream for Moderate to Severe Papulopustular Rosacea. Completed, enrolled 630 participants across 1 site.
Detailed Summary
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedJul 2016
Primary CompletionNov 2016
Study CompletionDec 2016
TodayJul 2026
First PostedJul 21, 2016
Enrollment StartJun 1, 2016
Primary CompletionNov 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.9 years ago
Interventions
Ivermectin Cream, 1%drug
Placebo/Vehicle creamdrug